Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · IEX Real-Time Price · USD
7.61
-0.26 (-3.30%)
At close: Jul 19, 2024, 4:00 PM
7.74
+0.13 (1.71%)
Pre-market: Jul 22, 2024, 7:36 AM EDT

Recursion Pharmaceuticals Revenue

Recursion Pharmaceuticals had revenue of $46.24M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $13.79M with 13.68% year-over-year growth. In the year 2023, Recursion Pharmaceuticals had annual revenue of $44.58M with 11.88% growth.

Revenue (ttm)
$46.24M
Revenue Growth
-0.88%
P/S Ratio
42.97
Revenue / Employee
$92,470
Employees
500
Market Cap
1.99B USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202344.58M4.73M11.88%
Dec 31, 202239.84M29.67M291.46%
Dec 31, 202110.18M6.22M156.89%
Dec 31, 20203.96M1.64M70.85%
Dec 31, 20192.32M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
BrightSpring Health Services 9.37B
Novavax 996.61M
Amphastar Pharmaceuticals 676.21M
10x Genomics 625.45M
NovoCure 525.66M
Catalyst Pharmaceuticals 411.35M
Immunocore Holdings 264.25M
Arvinas 71.30M
Revenue Rankings